期刊
NATURE COMMUNICATIONS
卷 8, 期 -, 页码 -出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/ncomms14756
关键词
-
资金
- Klempfner Epigenetics Fellowship
- Haematology Society of Australia and New Zealand
- National Breast Cancer Foundation
- Victorian Cancer Agency
- National Health and Medical Research Council of Australia [1104549]
- Abbvie
- Janssen
- National Health and Medical Research Council of Australia [1104549] Funding Source: NHMRC
- National Breast Cancer Foundation [ECF-14-027] Funding Source: researchfish
Several novel therapeutics are poised to change the natural history of chronic lymphocytic leukaemia (CLL) and the increasing use of these therapies has highlighted limitations of traditional disease monitoring methods. Here we demonstrate that circulating tumour DNA (ctDNA) is readily detectable in patients with CLL. Importantly, ctDNA does not simply mirror the genomic information contained within circulating malignant lymphocytes but instead parallels changes across different disease compartments following treatment with novel therapies. Serial ctDNA analysis allows clonal dynamics to be monitored over time and identifies the emergence of genomic changes associated with Richter's syndrome (RS). In addition to conventional disease monitoring, ctDNA provides a unique opportunity for non-invasive serial analysis of CLL for molecular disease monitoring.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据